Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + metformin (Boehringer Ingelheim)
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Synjardy XR is a fixed-dose combination of empagliflozin and metformin hydrochloride extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption and increases urinary glucose excretion. Metformin is a biguanide that improves glucose tolerance by lowering both basal and postprandial plasma glucose; it exerts its effects by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. The extended-release formulation allows for once-daily dosing, which can improve patient adherence compared to immediate-release formulations. It was developed through a partnership between Boehringer Ingelheim and Eli Lilly.
- Brand names
- Synjardy XR
- Other names
- empagliflozin/metformin hydrochloride extended-release
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on empagliflozin + metformin (Boehringer Ingelheim).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + metformin (Boehringer Ingelheim).